


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-08)	PADELIPORFIN
PRONUNCIATION	pa del'' i por' fin
THERAPEUTIC CLAIM	Treatment of prostate cancer

1. Palladate(2-), [(7*S*,8*S*,17*R*,18*R*)-13-acetyl-18-ethyl-7,8-dihydro-5-(2-methoxy-2-oxoethyl)-2,8,12,17-tetramethyl-3-[(2-sulfoethyl)amino]carbonyl]-21*H*,23*H*-porphine-7-propanoato(4-)-κ*N*²¹,κ*N*²²,κ*N*²³,κ*N*²⁴]-, (*SP*-4-2)-
2. (*SP*-4-2)-[(7*S*,8*S*,17*R*,18*R*)-13-acetyl-18-ethyl-7,8-dihydro-5-(2-methoxy-2-oxoethyl)-2,8,12,17-tetramethyl-3-[(2-sulfoethyl)carbamoyl]-21*H*,23*H*-porphine-7-propanoato(4-)-κ*N*²¹,κ*N*²²,κ*N*²³,κ*N*²⁴]-palladate(2-)

STRUCTURAL FORMULA



MOLECULAR FORMULA	C ₃₇ H ₄₃ N ₅ O ₉ PdS
MOLECULAR WEIGHT	840.3
TRADEMARK	TOOKAD®
SPONSOR	Steba Biotech S.A.
CODE DESIGNATIONS	WST11
<u>CAS</u> REGISTRY NUMBER	886845-72-3
UNII	EEO29FZT86
WHO NUMBER	8679

SCS